Response to letter regarding article, "adherence to third european cooperative acute stroke study 3-to 4.5-hour exclusions and association with outcome: Data from get with the guidelines-stroke"

Stroke

Volumn 46, Issue 1, 2015, Pages e16-

  Cronin, Carolyn A ^a   Smith, Eric E ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; EUROPE; HISTORY; HUMAN; LETTER; MEDICAL HISTORY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; STROKE;

HUMANS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84920285757     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.007906     Document Type: Letter

References (3)

1. Sen S, Powers WJ. Letter by Sen et al regarding article, "Adherence to third European cooperative acute stroke study 3-to 4.5-hour exclusions and association with outcome: data from get with the guidelines-stroke." Stroke. 2015;46:e15. doi: 10.1161/STROKEAHA.114.007865.
2. Cronin CA, Sheth KN, Zhao X, Messé SR, Olson DM, Hernandez AF, et al. Adherence to third European cooperative acute stroke study 3-to 4.5-hour exclusions and association with outcome: data from get with the guidelines-stroke. Stroke. 2014;45:2745-2749. doi: 10.1161/STROKEAHA.114.005443.
3. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials [published online ahead of print August 6, 2014]. Lancet. http://www.sciencedirect.com/science/article/pii/S0140673614605845. Accessed October 24, 2014.